Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation

22:03 EDT 14 Jul 2018 | ChinaBio Today

Deals and Financings

Trials and Approvals

Suzhou CStone Pharma was approved to start China trials of its PD-1 mAb, after a short, four-month review period;
Adagene of Suzhou was approved to begin US trials of its lead product, ADG-106, in patients with advanced solid tumors and non-Hodgkin lymphoma.

Stock Symbols: (SHA: 600535) (SHA: 600535) (P: TNG) (NYSE AMERICAN:IBIO) (NYSE: NVS) (F: MRK) (HK: 0700)

Share this with colleagues:

More From BioPortfolio on "Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation"